Epidemiological and demographic characteristics of gynecological sarcoma: Results of the prospective intergroup registry for gynecological sarcoma in Germany (REGSA–NOGGO RU1).

Authors

null

Eva Roser

Klinik Für Gynäkologie Mit Zentrum Für Onkologische Chirurgie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

Eva Roser , Anne-Sophie Noack , Dario Zocholl , Stefan Kommoss , Philipp Harter , Matthias Kalder , Eva-Katherina Egger , Paul Buderath , Christian Marth , Uwe Andreas Ulrich , Maximillian Klar , Michael Weigel , Lea Franziska Traub , Hans-Georg Strauss , Lars Ch. Hanker , Pauline Wimberger , Martin Pölcher , Felix Beck , Klaus Pietzner , Jalid Sehouli

Organizations

Klinik Für Gynäkologie Mit Zentrum Für Onkologische Chirurgie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany, Charité - University Medicine of Berlin, corporate member of Free University of Berlin and Humboldt University of Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany, Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany, AGO Study Group & Evang. Kliniken Essen-Mitte, Essen, Germany, UKGM - Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Marburg, Germany, Universitätsfrauenklinik Bonn, Gynäkologische Onkologie, Bonn, Germany, University Hospital of Essen, Essen, Germany, AGO-Austria and Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria, Department of Gynecology & Obstetrics, Martin-Luther Hospital Berlin, Berlin, Germany, AGO & University Hospital Freiburg, Department of Gynecology, Freiburg, Germany, Frauenklinik, Leopoldina-Krankenhaus, Schweinfurt, Germany, Klinikum rechts der Isar, München, Germany, Department of Obstetrics and Gynecology, University Hospital Halle, Halle, Germany, University of Schleswig-Holstein, Lübeck, Germany, North-Eastern German Society of Gynecological Oncology (NOGGO) and Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, Rotkreuzklinikum München Frauenklinik, München, Germany, Charité Universitätsmedizin Berlin, Klinik für Gynäkologie Campus Charité Virchow, Berlin, Germany, Charité Universitätsmedizin Berlin, Department of Gynaecology, European Competence Center for Ovarian Cancer, Charité Campus Virchow-Klinikum, Berlin, Germany, North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany

Research Funding

Pharmaceutical/Biotech Company

Background: Gynecological sarcomas (GS) are orphan diseases associated with poor prognosis. With the aim to improve our understanding of GS, the German registry for gynecological sarcoma (REGSA) prospectively recorded patients’ data with GS treated in real-life clinical practice at initial diagnosis and the time of relapse. Herein, we present the analysis of demographic and epidemiological data of patients with GS at the time of initial diagnosis. Methods: An exploratory analysis among different histological subtypes of GS was performed and patients’ data were compared to data of the healthy standard population. We analyzed the following variables: age, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, ethnicity, lifestyle habits, pregnancies, and comorbidities. Results: Data of 389 patients with GS were descriptively evaluated. Leiomyosarcoma (LMS) was the most common histological subtype (47.3%), followed by low-grade endometrial stromal sarcoma (LG-ESS; 17.7%), high-grade ESS (HG-ESS; 10.4%), adenosarcoma (AS; 9.1%) and undifferentiated uterine sarcoma (UUS; 6.2%). Overall, 9.4% of all GS were classified as “other” rarer histological subtypes. The mean age of patients was 57.4 years. The youngest were the patients with LG-ESS (54.3 years), whereas patients with AS were the oldest ones (61.7 years). There were no statistically significant differences in average age nor in BMI among patients with different histological subtypes of GS. In contrast, compared to the standard population, the BMI of patients with GS was significantly higher (27.5 kg/m²vs 25.1 kg/m², p< 0.001). Overall, 70.7% of all patients with LMS had FIGO stage I or II. Therefore, it is not surprising that most of patients had ECOG performance status 0 (68.3%). According to the countries of recruitment (i.e. Germany, Austria, Switzerland), 92.8% of patients were Caucasian. REGSA patients were less likely to be smokers compared to the national average of German women (13.4% vs 18.6%). One or two births per patient were reported in 58.2% of patients. In comparison the current birth ratio in Germany is approximately 1.5 children per woman. Hypertension was the most common comorbidity as observed in 33.2% of all cases, followed by thyroid diseases (18.6%). The prevalence of hypertension in the German female standard population is approximately 30% and approximately every third person will be affected by thyroid diseases in their lifetime. Conclusions: REGSA data showed no statistically significant differences in terms of demographic variables between different histological subtypes of GS, whereas statistically significant difference such as BMI was identified as compared to the standard population. Further research is needed to specify risk factors of GS in order to promote primary prevention of this fatal disease.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e17630)

DOI

10.1200/JCO.2022.40.16_suppl.e17630

Abstract #

e17630

Abstract Disclosures

Similar Abstracts

Abstract

2021 Genitourinary Cancers Symposium

Renal sarcomas: Epidemiology, treatment and outcomes.

First Author: Johannes Uhlig

First Author: Maria Cristina Cuartas Mesa